Terray Therapeutics today announced its $60 million Madrona-led Series A. We have worked with the company for over two years throughout the pandemic and are excited to speak more broadly about the company, its mission and our belief in the power of innovation intersections.
Interested in hearing from the founders and Chris? Check out this Founded & Funded podcast published in February 2022.
When pharmaceutical companies set out to discover new small molecule therapies, they typically follow the same pattern: years of experiments in biology followed by a slow process of designing and testing potential drug candidates. Although some new methods have helped improve this process, the basic steps and timing are the same.
We believe there is huge untapped potential in the application of machine learning to improve the speed and accuracy of drug discovery. Yet even the most powerful artificial intelligence cannot operate with insufficient or obscure data.
We believe there is huge untapped potential in the application of machine learning to improve the speed and accuracy of drug discovery. Yet even the most powerful artificial intelligence cannot work with insufficient or obscure data.
Terray Therapeutics creates a chemistry engine that brings together the two pieces of the puzzle – modern AI and machine learning models and the most comprehensive chemical datasets in the world. Today, we are thrilled to announce our lead investment in their $60 million Series A fundraising.
We started working with founders Jacob and Eli Berlin when we invested in their funding round. Prior to founding Terray, Jacob had spent eight years as a professor at the Beckman Research Institute at the Los Angeles-based City of Hope Comprehensive Cancer Center, developing the underlying technology and building the company‘s early stages. The entire Madrona team was blown away by the wet lab platform they had built and its ability to quickly create large chemical libraries and then screen them in minutes. Since then, the core technology has seen rapid progress: Terray has industrialized its technology and now measures billions of precise chemical data points daily using its existing libraries of drug candidates, and the company is continuously synthesizing libraries with several million new drug candidates – truly unprecedented. speed, scale and precision in the world of biotechnology. With its core technology, Terray transforms the drug discovery process from a tedious, low-throughput task into a machine learning-driven data problem.
By focusing on the scale and quality of their data, Terray enables AI-driven drug development. The team applies ML to every round of screening, mapping every chemical compound to potential causes of disease and generating deep insights into billions of interactions. The integrated wet lab and AI approach is key to the power of the platform and helps close the data science loop with real experimental data.
We believe Terray holds the key to improving drug discovery processes – its ability to generate and accurately measure new datasets enables the rapid iteration of scientific hypotheses and the ability to arrive at drugs at small molecules that save lives at a much faster rate than possible with traditional techniques.
At Madrona, our thesis on the intersections of innovation revolves around combining the power of data and computing with life science research. Bringing these two disciplines together creates an entirely new field of biotechnology innovation. This often means combining machine learning with wet lab innovation, as in the case of Terray. We believe Terray holds the key to improving drug discovery processes – its ability to generate and accurately measure new datasets enables the rapid iteration of scientific hypotheses and the ability to arrive at drugs at small molecules that save lives at a much faster rate than possible with traditional techniques.
Working with the Terray team has been a joy over the past two years. Brothers Jacob and Eli Berlin founded the company, using their unique skills from decades of innovative scientific research and finance, respectively. Since then, they have built a world-class management team with deep expertise in investigational and computational drug discovery and development and assembled a team of 50 world-class data and experimental scientists who passionately pursue building something that will benefit society. We couldn’t be more excited to deepen our partnership with them alongside a syndicate of world-class investors.
Terray’s vision is emblematic of why we are passionate about our thesis on the intersections of innovation and a great example of applying the power of modern software and machine learning to previously unsolvable scientific problems.